Glypican-3: A novel diagnostic marker for hepatocellular carcinoma and more

Advances in Anatomic Pathology

Volumn 16, Issue 2, 2009, Pages 125-129

  Kandil, Dina H ^a,b   Cooper, Kumarasen ^a  

^a UNIVERSITY OF VERMONT   (United States)

^b FLETCHER ALLEN HEALTH CARE   (United States)

Author keywords

Glypican 3; Hepatoblastoma; Hepatocellular carcinoma; Squamous cell carcinoma of the lung; Yolk sac tumors

Indexed keywords

ALPHA FETOPROTEIN; GLYPICAN 3; ONCOFETAL ANTIGEN; TUMOR MARKER;

CANCER DIAGNOSIS; CELL DIFFERENTIATION; CELL GROWTH; CYTOLOGY; DIFFERENTIAL DIAGNOSIS; GERM CELL TUMOR; HEPATITIS C; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; MEDULLOBLASTOMA; MELANOMA; NEPHROBLASTOMA; NEUROBLASTOMA; PRIORITY JOURNAL; REVIEW; SENSITIVITY AND SPECIFICITY; SQUAMOUS CELL CARCINOMA; TUMOR SUPPRESSOR GENE; YOLK SAC TUMOR;

CARCINOMA, HEPATOCELLULAR; FEMALE; GLYPICANS; HUMANS; LIVER NEOPLASMS; LUNG NEOPLASMS; MALE; OVARIAN NEOPLASMS; TESTICULAR NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 68649097790     PISSN: 10724109     EISSN: 15334031     Source Type: Journal    
DOI: 10.1097/PAP.0b013e3181992455     Document Type: Review

References (40)

1. Filmus J. Glypicans in growth control and cancer. Glycobiology. 2001;11:19R-23R.
2. Yayon A, Klagsbrun M, Esko JD, et al. Cell surface, heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor. Cell. 1991;64:841-848. (Pubitemid 121001170)
3. Li M, Choo B, Wong ZM, et al. Expression of OCI-5/glypican 3 during intestinal morphogenesis: regulation by cell shape in intestinal epithelial cells. Exp Cell Res. 1997;235:3-12. (Pubitemid 27381675)
4. Song HH, Shi W, Xiang YY, et al. The loss of glypican-3 induces alterations in Wnt signaling. J Biol Chem. 2005;280:2116-2125.
5. Pilia G, Hughes-Benzie RM, MacKenzie A, et al. Mutations in GPC3, a glypican gene, cause the Simpson-Golabi-Behmel overgrowth syndrome. Nat Genet. 1996;12:241-247. (Pubitemid 26080081)
6. Hughes-Benzie RM, Pilia G, Xuan JY, et al. Simpson-Golabi-Behmel syndrome: genotype/phenotype analysis of 18 affected males from 7 unrelated families. Am J Med Genet. 1996;66:227-234. (Pubitemid 27002956)
7. Khan S, Blackburn M, Mao DL, et al. Glypican-3 (GPC3) expression in human placenta: localization to the differentiated syncytiotrophoblast. Histol Histopathol. 2001;16:71-78. (Pubitemid 32094024)
8. Lopez LJ, Marrero JA. Hepatocellular carcinoma. Curr Opin Gastroenterol. 2004;20:248-253.
9. Lopez JB. Recent developments in the first detection of hepatocellular carcinoma. Clin Biochem Rev. 2005;26:65-79.
10. Capurro M, Filmus J. Glypican-3 as a serum marker for hepatocellular carcinoma. Cancer Res. 2005;65:372; author reply 372-373.
11. Capurro M, Wanless IR, Sherman M, et al. Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology. 2003;125:89-97. (Pubitemid 36799110)
12. Hippo Y, Watanabe K, Watanabe A, et al. Identification of soluble NH2-terminal fragment of glypican-3 as a serological marker for early-stage hepatocellular carcinoma. Cancer Res. 2004;64:2418-2423. (Pubitemid 38523895)
13. Hsu HC, Cheng W, Lai PL. Cloning and expression of a developmentally regulated transcript MXR7 in hepatocellular carcinoma: biological significance and temporospatial distribution. Cancer Res. 1997;57:5179-5184. (Pubitemid 27498138)
14. Zhou XP, Wang HY, Yang GS, et al. Cloning and expression of MXR7 gene in human HCC tissue. World J Gastroenterol. 2000;6:57-60. (Pubitemid 30093063)
15. Filmus J, Capurro M. Glypican-3 and alphafetoprotein as diagnostic tests for hepatocellular carcinoma. Mol Diagn. 2004;8:207-212. (Pubitemid 40994223)
16. Capurro MI, Xiang YY, Lobe C, et al. Glypican-3 promotes the growth of hepatocellular carcinoma by stimulating canonical Wnt signaling. Cancer Res. 2005;65:6245-6254. (Pubitemid 40994410)
17. Wang XY, Degos F, Dubois S, et al. Glypican-3 expression in hepatocellular tumors: diagnostic value for preneoplastic lesions and hepatocellular carcinomas. Hum Pathol. 2006;37:1435-1441. (Pubitemid 44739946)
18. Abdul-Al HM, Makhlouf HR, Wang G, et al. Glypican-3 expression in benign liver tissue with active hepatitis C: implications for the diagnosis of hepatocellular carcinoma. Hum Pathol. 2008;39:209-212.
19. Kandil D, Leiman G, Allegretta M, et al. Glypican-3 immunocytochemistry in liver fine-needle aspirates: a novel stain to assist in the differentiation of benign and malignant liver lesions. Cancer. 2007;111:316-322.
20. Ligato S, Mandich D, Cartun RW. Utility of glypican-3 in differentiating hepatocellular carcinoma from other primary and metastatic lesions in FNA of the liver: an immunocytochemical study. Mod Pathol. 2008;21:626-631. (Pubitemid 351589657)
21. Shafizadeh N, Ferrell LD, Kakar S. Utility and limitations of glypican-3 expression for the diagnosis of hepatocellular carcinoma at both ends of the differentiation spectrum. Mod Pathol. 2008;21:1011-1018.
22. Yamauchi N, Watanabe A, Hishinuma M, et al. The glypican 3 oncofetal protein is a promising diagnostic marker for hepatocellular carcinoma. Mod Pathol. 2005;18:1591-1598. (Pubitemid 41670658)
23. Man XB, Tang L, Zhang BH, et al. Upregulation of glypican-3 expression in hepatocellular carcinoma but downregulation in cholangiocarcinoma indicates its differential diagnosis value in primary liver cancers. Liver Int. 2005;25:962-966. (Pubitemid 41404016)
24. Libbrecht L, Severi T, Cassiman D, et al. Glypican-3 expression distinguishes small hepatocellular carcinomas from cirrhosis, dysplastic nodules, and focal nodular hyperplasia-like nodules. Am J Surg Pathol. 2006;30:1405-1411. (Pubitemid 44655475)
25. Zynger DL, Gupta A, Luan C, et al. Expression of glypican 3 in hepatoblastoma: an immunohistochemical study of 65 cases. Hum Pathol. 2008;39:224-230.
26. Sugimura J, Foster RS, Cummings OW, et al. Gene expression profiling of early- and late-relapse nonseminomatous germ cell tumor and primitive neuroectodermal tumor of the testis. Clin Cancer Res. 2004;10:2368-2378. (Pubitemid 38445695)
27. Iczkowski KA, Butler SL. New immunohistochemical markers in testicular tumors. Anal Quant Cytol Histol. 2006;28:181-187.
28. Ota S, Hishinuma M, Yamauchi N, et al. Oncofetal protein glypican-3 in testicular germ-cell tumor. Virchows Arch. 2006;449:308-314. (Pubitemid 44367971)
29. Zynger DL, Dimov ND, Luan C, et al. Glypican 3: a novel marker in testicular germ cell tumors. Am J Surg Pathol. 2006;30:1570-1575. (Pubitemid 44808793)
30. Zynger DL, Everton MJ, Dimov ND, et al. Expression of glypican 3 in ovarian and extragonadal germ cell tumors. Am J Clin Pathol. 2008;130:224-230.
31. Saikali Z, Sinnett D. Expression of glypican 3 (GPC3) in embryonal tumors. Int J Cancer. 2000;89:418-422. (Pubitemid 30750416)
32. Toretsky JA, Zitomersky NL, Eskenazi AE, et al. Glypican-3 expression in Wilms tumor and hepatoblastoma. J Pediatr Hematol Oncol. 2001;23:496-499. (Pubitemid 33123699)
33. White GR, Kelsey AM, Varley JM, et al. Somatic glypican 3 (GPC3) mutations in Wilms' tumour. Br J Cancer. 2002;86:1920-1922.
34. Powell CA, Xu G, Filmus J, et al. Oligonucleotide microarray analysis of lung adenocarcinoma in smokers and nonsmokers identifies GPC3 as a potential lung tumor suppressor. Chest. 2002;121:6S-7S. (Pubitemid 34248308)
35. Kim H, Xu GL, Borczuk AC, et al. The heparan sulfate proteoglycan GPC3 is a potential lung tumor suppressor. Am J Respir Cell Mol Biol. 2003;29:694-701. (Pubitemid 38054366)
36. Aviel-Ronen S, Lau SK, Pintilie M, et al. Glypican-3 is overexpressed in lung squamous cell carcinoma, but not in adenocarcinoma. Mod Pathol. 2008;21:817-825. (Pubitemid 351896655)
37. Nakatsura T, Kageshita T, Ito S, et al. Identification of glypican-3 as a novel tumor marker for melanoma. Clin Cancer Res. 2004;10:6612-6621. (Pubitemid 39346558)
38. Esheba GE, Pate LL, Longacre TA. Oncofetal protein glypican-3 distinguishes yolk sac tumor from clear cell carcinoma of the ovary. Am J Surg Pathol. 2008;32:600-607.
39. Stadlmann S, Gueth U, Baumhoer D, et al. Glypican-3 expression in primary and recurrent ovarian carcinomas. Int J Gynecol Pathol. 2007;26:341-344. (Pubitemid 46986073)
40. Hishinuma M, Ohashi KI, Yamauchi N, et al. Hepatocellular oncofetal protein, glypican 3 is a sensitive marker for alpha-fetoprotein-producing gastric carcinoma. Histopathology. 2006;49:479-486. (Pubitemid 44631620)